Results 71 to 80 of about 5,803 (182)

Disrupting Viral Persistence: CRISPR/Cas9‐Based Strategies for Hepatitis B and C Treatment, and Challenges

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li, Akmal Zubair, Safa Wdidi, Shan He   +3 more
wiley   +1 more source

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C

International Journal of Hepatology, Volume 2026, Issue 1, 2026.
Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Seiichi Tawara, Asuka Watanabe, Junya Yamaguchi, Mai Omi, Tetsuro Miyazaki, Haruka Taguchi, Ryosuke Kiyota, Takuo Yamai, Shoichiro Kawai, Takuya Inoue, Takayuki Yakushijin, Dirk Uhlmann   +11 more
wiley   +1 more source

The baseline resistance-associated substitutions (RASs) and virologic failure in patients treated with sofosbuvir and ledipasvir.

, 2018
The baseline resistance-associated substitutions (RASs) and virologic failure in patients treated with sofosbuvir and ledipasvir.
Takeshi Kure (5328974), Tsutomu Tamai (496424), Kazuaki Tabu (496423), Kohei Oda (496422), Takeshi Hori (166759), Akihiro Moriuchi (496425), Masafumi Hashiguchi (5328965), Yukiko Inada (5328971), Kotaro Kumagai (496421), Hirofumi Uto (496418), Yasunari Hiramine (5328956), Seiichi Mawatari (496417), Kunio Fujisaki (5328962), Oki Taniyama (5328968), Sho Ijuin (5328953), Akio Ido (496419), Ai Kasai (5328959)   +16 more
core   +1 more source

Development and Validation of Stability indicating RP- HPLC method for Simultaneous Estimation of Sofosbuvir and Ledipasvir in Bulk Tablet Dosage Form [PDF]

, 2019
The present research work describes a simple, accurate, precise, effective, Stability indicating RP-HPLC method for simultaneous estimation of Sofosbuvir and Ledipasvir in their tablet dosage form.
Dalavi, P.R., Bhawar, S.B., Mankar, S.D.
core   +1 more source

Advances and Challenges in Model‐Informed Precision Dosing of Antimicrobials for Pediatric Patients

Journal of Clinical Pharmacy and Therapeutics, Volume 2026, Issue 1, 2026.
Precision medicine has transformed healthcare by moving toward individualized treatment strategies, yet dosing optimization for pediatric patients remains a complex challenge. Therapeutic drug monitoring (TDM), a widely used practice in clinical settings, provides a foundation for achieving therapeutic goals but poses significant limitations ...
Jing Kai Lam, Xiaoyan Yang, Baharudin Ibrahim, Amirrudin Kamsin, Jinxin Zhao, S. Y. Amy Cheung, Xiaofen Liu, Jamaludin Elis, Nusaibah Abdul Rahim, Yu-Wei Lin, Zhiwen Luo   +10 more
wiley   +1 more source

Sofosbuvir/Ledipasvir - new pharmaceutical approach against hepatitis C

, 2015
Introduction: Hepatitis C is an inflammation of the liver, which is caused by a hepatitis C virus (HCV). Over 170 million people worldwide are infected with HCV.
Gergova, Dayana, Tonev, Krasen, Cherneva, Totka, Kumanov, Ivo, Georgieva, Patrisiya, Georgieva, Svetlana, Stoeva, Stanila   +6 more
core   +1 more source

Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada

Canadian Journal of Gastroenterology and Hepatology, 2015
BACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to ...
Sergio M Borgia, Adenike Rowaiye
doaj   +1 more source

HCV virologic response (SVR12) following 12 weeks of ledipasvir/sofosbuvir treatment overall and by subgroup.

, 2020
HCV virologic response (SVR12) following 12 weeks of ledipasvir/sofosbuvir treatment overall and by subgroup.
Thai Nguyen-Cleary (4235302), Mamta K. Jain (8374734), Federico Hinestrosa (8374737), Stephanie Cox (8374758), Gregory D. Huhn (8374731), Moti Ramgopal (4559698), David M. Asmuth (8374740), Shuping Jiang (8374755), Richard H. Haubrich (8374767), David Piontkowsky (2795320), Lorenzo Rossaro (8374764), Jihad Slim (8374743), Deborah Goldstein (8374746), Moupali Das (364170), Shauna Applin (8374749), Julie H. Ryu (8374752), Bill Guyer (8374761)   +16 more
core   +1 more source

Evaluation of Characteristics and Ethnic Sensitivity for FDA‐Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy

The Journal of Clinical Pharmacology, Volume 65, Issue 11, Page 1381-1391, November 2025.
Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Kei Fukuhara, Yusuke Tanetsugu, Shinsuke Wada, Chieko Muto, Norisuke Kawai   +4 more
wiley   +1 more source

A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study

, 2017
The effectiveness of a 12-week course of sofosbuvir-ledipasvir in treatment-experienced HCV genotype 1b-infected patients with cirrhosis is still under debate.
Andriulli, A, P. Gatti, R. Francavilla, Ippolito, A. M., Messina, V, Francavilla, R, G. Lauletta, Iannone, A., A. Di Leo, Conti, F, E. Shahini, Brancaccio, G., TUNDO, Antonio, Napoli, N, A. M. Ippolito, Morisco, F., Tundo, P, Santantonio, T, Brancaccio, G, F. Morisco, Tundo, P., Iannone, A, Shahini, E, Milella, M, A. Smedile, F. Conti, Termite, A P, Di Leo, A, Masetti, C., N. Napoli, Conti, F., A. P. Termite, C. Masetti, Smedile, A, Pesce, F., Barone, M, Barone, M., Francavilla, R., Masetti, C, T. Santantonio, F. Pesce, G. Brancaccio, Termite, A. P., Ippolito, A M, Morisco, F, Smedile, A., A. Andriulli, Santantonio, T., Lauletta, G., P. Tundo, A. Iannone, Lauletta, G, Di Leo, A., Pesce, F, Andriulli, A., Shahini, E., Messina, V., Gatti, P., M. Barone, Napoli, N., Milella, M., Gatti, P, M. Milella, V. Messina   +63 more
core   +1 more source